By Linda N. Geng et al.
Source Jamanetwork
Key Points
Question What is the efficacy of 15 days of nirmatrelvir-ritonavir for improving select symptoms of postacute sequelae of SARS-CoV-2 infection (PASC)?
Findings This randomized clinical trial including 155 participants with PASC symptoms (≥3 months’ duration) found that a 15-day course of nirmatrelvir-ritonavir in a mostly vaccinated study cohort was generally safe, but did not show significant benefit in improving fatigue, brain fog, body aches, cardiovascular symptoms, shortness of breath, or gastrointestinal symptoms.
Meaning These findings indicate that further studies are needed to determine the role of antivirals in the treatment of PASC.
Read more https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2819901